The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient expectations. This dynamic environment is not merely reshaping how medical services are delivered, but fundamentally redefining the entire patient experience and the
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desperate for deal approval.
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug pegozafermin.
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout The company is now focusing on MASH, a form of fatty liver disease common in people with obesity and type 2 diabetes.
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
2 High-Yield Dividend ETFs You Can Buy With $200 in September and Hold Forever You don't need to be rich to begin building a passive income stream that could fuel your retirement dreams.
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.
This Biotech Stock Could Soar on Upcoming Clinical Data This weight loss drugmaker may be significantly undervalued right now.
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid buildup.
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
